1584121-99-2

Basic information

• Product Name: 5-((2,4-dimethoxynaphthalen-1-yl)methylene)-2-thioxodihydropyrimidine-4,6(1H,5H)-dione
• Synonyms: 5-((2,4-dimethoxynaphthalen-1-yl)methylene)-2-thioxodihydropyrimidine-4,6(1H,5H)-dione;IT901
• CAS NO: 1584121-99-2
• Molecular Formula: C17H14N2O4S
• Molecular Weight: 342.36906
• EINECS: -0
• Mol File: 1584121-99-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-((2,4-dimethoxynaphthalen-1-yl)methylene)-2-thioxodihydropyrimidine-4,6(1H,5H)-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 5-((2,4-dimethoxynaphthalen-1-yl)methylene)-2-thioxodihydropyrimidine-4,6(1H,5H)-dione(1584121-99-2)
• EPA Substance Registry System: 5-((2,4-dimethoxynaphthalen-1-yl)methylene)-2-thioxodihydropyrimidine-4,6(1H,5H)-dione(1584121-99-2)

Safety Data

• Hazardous Substances Data: 1584121-99-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
IT 901 is used as an inhibitor for the NF-κB subunit c-Rel, which plays a crucial role in regulating cellular responses to various stimuli, including stress, cytokines, and bacterial or viral antigens. By inhibiting c-Rel, IT 901 can potentially modulate the immune response and has shown promise in the development of therapeutic strategies for various diseases.
Used in Anticancer Applications:
IT 901 is used as an anticancer agent, exhibiting antitumor properties in both in vitro and in vivo studies. Its ability to inhibit the NF-κB subunit c-Rel may contribute to its antitumor effects, as the NF-κB pathway is often dysregulated in cancer cells, promoting their survival and proliferation. IT 901 may be employed in the development of novel cancer treatments, potentially in combination with other therapeutic agents to enhance efficacy and overcome drug resistance.
Used in Drug Delivery Systems:
To improve the delivery, bioavailability, and therapeutic outcomes of IT 901, various drug delivery systems can be employed. These systems may include organic and metallic nanoparticles, liposomes, or other advanced drug carriers designed to enhance the stability, solubility, and targeted delivery of IT 901 to cancer cells. This approach can help to maximize the drug's therapeutic potential while minimizing potential side effects and toxicity.